Political and Legislative
Democrats Probe the Controversial FDA Approval of Alzheimer’s Medication

Democratic leaders of two House committees are stepping up a probe of the Food and Drug Administration’s (FDA) controversial approval of the Alzheimer’s drug Aduhelm, pressing the agency for information on “anomalies” in the approval process.
In a letter to FDA sent Wednesday, House Energy and Commerce Committee Chairman Frank Pallone Jr. (D-N.J.) and Oversight and Reform Chairwoman Carolyn Maloney (D-N.Y.) said “significant questions” remain even after FDA staff briefed their panels.